Evidence map›Paper›PMID 41680473›Full record

ArticleGene therapy2026

Comprehensive forced degradation study revealing diverse chemical and physical degradation pathways of AAV8.

Kuan-Yu Lai, Song Nie, Yu-Chieh Ariel Chen, Timothy N Tiambeng, Shuli Tang, Yu Huang, Yuetian Yan, Shashwat Mishra, Humam Al-Rubaye, Aynur Hermann and 7 more

Abstract read
In one paragraph

Article in Gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kuan-Yu Lai *Formulation Development Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Song Nie *Analytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Yu-Chieh Ariel ChenFormulation Development Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.ORCID 0009-0006-7499-840X
Timothy N TiambengAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Shuli TangAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Yu HuangAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Yuetian YanAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Shashwat MishraTherapeutic Protein, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Humam Al-RubayeTherapeutic Protein, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Aynur HermannTherapeutic Protein, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Nina LiuProtein Biochemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Michael RosconiProtein Biochemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Ning LiAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Mohammed ShameemFormulation Development Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.
Shunhai WangAnalytical Chemistry Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA. shunhai.wang@regeneron.com.
Li ZhiFormulation Development Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA. li.zhi@regeneron.com.ORCID 0009-0004-8317-7385
Dingjiang LiuFormulation Development Group, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While recombinant adeno-associated virus (AAV) holds significant promise for effective and durable gene delivery for gene therapy, a thorough understanding of the critical quality attributes (CQAs) along with the degradation pathways of AAV under the various stresses that may occur during manufacturing, storage, and handling remains limited. To address this gap, we performed a comprehensive forced degradation study to elucidate the degradation pathways of AAV8 under a series of stress conditions, such as oxidation, extreme pH, high temperature, freeze-thaw, and agitation. Our results show that, under these stress conditions, distinct post-translational modifications (PTM), including methionine oxidation, asparagine deamidation, and aspartic acid isomerization, along with multiple physical degradation pathways, including capsid aggregation, viral protein fragmentation, and genome DNA leakage, could occur. Alterations in AAV8 biological activity were frequently attributed to the combination effect from chemical and physical degradation mechanisms. The results from this study provide a valuable insight into the establishment of stability-indicating methods and the identification of CQAs for AAV. It will also support the development of robust manufacturing process as well as stable and efficacious AAV gene therapy drug products.

Indexed as

DependovirusGenetic VectorsGene Therapy AgentsGenetic TherapyHumansHydrogen-Ion ConcentrationProtein Processing, Post-Translational

Identifiers

PMID41680473
PMCPMC13226045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.